(Q79299225)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

review article

1 reference

title

Osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Sue A Brown

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Clifford J Rosen

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

1 September 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

Medical Clinics of North America

21 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

1039-1063

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

Osteoporosis prevention, diagnosis, and therapy

21 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Who has osteoporosis? A conflict between clinical and public health perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

World-wide Projections for Hip Fracture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Prescribing by general practitioners after an osteoporotic fracture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Osteoporosis intervention following distal forearm fractures: a missed opportunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Population-based study of survival after osteoporotic fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

The worldwide problem of osteoporosis: insights afforded by epidemiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Epidemiology of hip fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

The association of radiographically detected vertebral fractures with back pain and function: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Epidemiology and outcomes of osteoporotic fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Proximal femur bone mineral levels of US adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Sources of interracial variation in bone mineral density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

The prevalence of osteoporosis: gender and racial comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Differences in bone mineral in young Asian and Caucasian Americans may reflect differences in bone size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Cross-sectional geometry, bone strength, and bone mass in the proximal femur in black and white postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Risk factors for falls among elderly persons living in the community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

High bone density due to a mutation in LDL-receptor-related protein 5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

A New Approach to the Development of Assessment Guidelines for Osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Risk of new vertebral fracture in the year following a fracture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Screening for osteoporosis in postmenopausal women: recommendations and rationale

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Prediction of the strength of the elderly proximal femur by bone mineral density and quantitative ultrasound measurements of the heel and tibia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Bone strength at clinically relevant sites displays substantial heterogeneity and is best predicted from site-specific bone densitometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Biochemical indices of bone turnover and the assessment of fracture probability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Emerging anabolic treatments for osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Treatment of postmenopausal osteoporosis with calcitriol or calcium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Calcitriol treatment is not effective in postmenopausal osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Effect of Dietary Protein on Bone Loss in Elderly Men and Women: The Framingham Osteoporosis Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Prevention of hip fracture in elderly people with use of a hip protector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Design of the Women’s Health Initiative Clinical Trial and Observational Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Esophagitis associated with the use of alendronate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

The analgesic role of calcitonin following osteoporotic fracture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Clinical review 123: Anabolic therapy for osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: prediction of long-term responses in spine and femur.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Treatment of painful osteoporotic vertebral fractures with percutaneous vertebroplasty or kyphoplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Monitoring skeletal changes by radiological techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Bone mineral density in diagnosis of osteoporosis: reference population, definition of peak bone mass, and measured site determine prevalence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2803%2900065-8

10.1016/S0025-7125(03)00065-8

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14621330%20AND%20SRC:MED&resulttype=core&format=json